Hopp til hovedinnhold

Dermatomyositt

Sist oppdatert: Sist revidert:
Sist revidert av:
Definisjon:
Er en idiopatisk inflammatorisk myopati som forekommer i tre hovedformer: polymyositt, dermatomyositt og sporadisk inklusjonslegeme myositt
Forekomst:
Tilstanden er sjelden og har to insidenstopper, en blant barn (juvenil dermatomyositt) og en blant voksne
Symptomer:
Muskelsmerter og utslett
Funn:
Muskelømhet og muskelatrofi, og et blåfiolett, makulært erytem med symmetrisk fordeling
Diagnostikk:
Blodprøver viser forhøyet SR og muskelenzymer. Serologiske prøver kan være aktuelle. Ellers bl.a. elektromyografi og muskelbiopsi
Behandling:
Aktuelle medikamenter er kortikosteroider, cyklosporin, azatioprin og metotreksat. Antimalariamiddel (klorokin, hydroxyklorokin) for behandling av hudutslett
  • Nasjonal kompetansetjeneste for svangerskap og revmatiske sykdommer (NKSR) - nettside 
  1. Femia AN. Dermatomyositis. Medscape, last updated Jul 21, 2021.
  2. Vleugels RA. Clinical manifestations of dermatomyositis and polymyositis in adults. UpToDate, last updated Oct 18, 2021. UpToDate  
  3. Andersson H, Bakland G, Dahl-Hofseth B, Aga Ljoså M-K. Inflammatoriske myopatier. Veileder. Norsk Revmatologisk Forening. Dato publisert 14.10.2021. norskrevmatologi.no  
  4. Chu LL, Rohekar G. Dermatomyositis. CMAJ. 2019;191(12):E340. PubMed  
  5. Selva-O'Callaghan A, Pinal-Fernandez I, Trallero-Araguás E, et al. Classification and management of adult inflammatory myopathies. The Lancet Neurology. 2018;17(9):816-28. PubMed  
  6. Amato AA, Barohn RJ. Evaluation and treatment of inflammatory myopathies. J Neurol Neurosurg Psychiatry 2009; 80:1060. PubMed  
  7. Bendewald MJ, Wetter DA, Li X, Davis MD. Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota. Arch Dermatol. 2010;146(1):26-30. PubMed  
  8. Bogdanov I, Kazandjieva J, Darlenski R, Tsankov N. Dermatomyositis: Current concepts. Clin Dermatol. 2018 Jul - Aug. 36 (4):450-458.
  9. Hoesly PM, Sluzevich JC, Jambusaria-Pahlajani A, et al. Association of antinuclear antibody status with clinical features and malignancy risk in adult-onset dermatomyositis. Journal of the American Academy of Dermatology, published November 17, 2018. doi:10.1016/j.jaad.2018.11.023 DOI  
  10. Tomasova Studynkova J, Charvat F, Jarosova K, et al. The role of MRI in the assessment of polymyositis and dermatomyositis. Rheumatology (Oxford). 2007;46:1174-1179. PubMed  
  11. Amato AA, Vleugels RA. Diagnosis and differential diagnosis of dermatomyositis and polymyositis in adults. UpToDate, last updated Feb 26, 2021. UpToDate  
  12. Alexanderson H, Dastmalchi M, Esbjörnsson-Liljedahl M, Opava CH, Lundberg IE. Benefits of intensive resistance training in patients with chronic polymyositis or dermatomyositis. Arthritis and rheumatism. 2007;57(5):768-77. PubMed  
  13. Aggarwal R, Charles-Schoeman C, Schessl J, et al. Trial of Intravenous Immune Globulin in Dermatomyositis. N Engl J Med 2022. pmid:36198179 PubMed  
  14. Carruthers EC, Choi HK, Sayre EC, et al. Risk of deep venous thrombosis and pulmonary embolism in individuals with polymyositis and dermatomyositis: a general population-based study. Ann Rheum Dis. 2014 Sep 5. pii: annrheumdis-2014-205800
  15. Antiochos BB, Brown LA, Li Z, Tosteson TD, Wortmann RL, Rigby WF. Malignancy is associated with dermatomyositis but not polymyositis in Northern New England, USA. J Rheumatol. 2009 Dec. 36(12):2704-10.
  16. Danieli MG, Gambini S, Pettinari L, Logullo F, Veronesi G, Gabrielli A. Impact of treatment on survival in polymyositis and dermatomyositis. A single-centre long-term follow-up study. Autoimmunity reviews. 2014;13(10):1048-54. PubMed  
  • Terje Johannessen, professor i allmennmedisin, Trondheim (tilpasning til NEL)

Tidligere fagmedarbeidere

  • Gunnar Husby, professor i revmatologi, Oslo Sanitetsforenings Revmatismesykehus, Universitetet i Oslo og Rikshospitalet, Oslo